Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
443.16
+10.09 (2.33%)
Mar 30, 2026, 4:00 PM EDT - Market closed
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,400 employees as of December 31, 2025. The number of employees increased by 300 or 4.92% compared to the previous year.
Employees
6,400
Change (1Y)
300
Growth (1Y)
4.92%
Revenue / Employee
$1,875,203
Profits / Employee
$617,688
Market Cap
112.58B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,400 | 300 | 4.92% |
| Dec 31, 2024 | 6,100 | 700 | 12.96% |
| Dec 31, 2023 | 5,400 | 600 | 12.50% |
| Dec 31, 2022 | 4,800 | 900 | 23.08% |
| Dec 31, 2021 | 3,900 | 500 | 14.71% |
| Dec 31, 2020 | 3,400 | 400 | 13.33% |
| Dec 31, 2019 | 3,000 | 500 | 20.00% |
| Dec 31, 2018 | 2,500 | 200 | 8.70% |
| Dec 31, 2017 | 2,300 | 150 | 6.98% |
| Dec 31, 2016 | 2,150 | 200 | 10.26% |
| Dec 31, 2015 | 1,950 | 120 | 6.56% |
| Dec 31, 2014 | 1,830 | 30 | 1.67% |
| Dec 31, 2013 | 1,800 | -400 | -18.18% |
| Dec 31, 2012 | 2,200 | 200 | 10.00% |
| Dec 31, 2011 | 2,000 | 309 | 18.27% |
| Dec 31, 2010 | 1,691 | 259 | 18.09% |
| Dec 31, 2009 | 1,432 | 99 | 7.43% |
| Dec 31, 2008 | 1,333 | 183 | 15.91% |
| Dec 31, 2007 | 1,150 | 188 | 19.54% |
| Dec 31, 2006 | 962 | 149 | 18.33% |
| Dec 31, 2005 | 813 | 77 | 10.46% |
| Dec 31, 2004 | 736 | 12 | 1.66% |
| Dec 31, 2003 | 724 | -256 | -26.12% |
| Dec 31, 2002 | 980 | -20 | -2.00% |
| Dec 31, 2001 | 1,000 | 545 | 119.78% |
| Dec 31, 2000 | 455 | 102 | 28.90% |
| Dec 31, 1999 | 353 | 13 | 3.82% |
| Dec 31, 1998 | 340 | 120 | 54.55% |
| Dec 31, 1997 | 220 | 42 | 23.60% |
| Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| argenx SE | 1,599 |
VRTX News
- 12 days ago - TrumpRx lists many medicines at prices higher than paid in UK - Reuters
- 19 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia
- 20 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 20 days ago - Vertex passes key test In quest to treat kidney diseases - CNBC
- 21 days ago - Vertex's kidney disease drug meets main goal in late-stage trial - Reuters
- 21 days ago - Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - Business Wire
- 25 days ago - Vertex to Participate in Upcoming March Investor Conferences - Business Wire